Clinical practices and treatment preferences of meropenem in the management of multidrug-resistant infections in Indian settings
Abstract
Background:
Antimicrobial resistance, particularly due to multidrug-resistant (MDR) gram-negative pathogens, poses a major therapeutic challenge in India. Despite several clinical studies on the effectiveness of meropenem in various infections, there is a dearth of studies among clinicians.
Aim:
To evaluate expert opinion on the clinical use of meropenem in the management of MDR infections in Indian clinical settings.
Methods:
This cross-sectional study employed a 23-item, multiple-choice questionnaire to gather expert opinions from clinicians with MDR management experience in Indian settings. The questionnaire covered current practices, clinical observations, and perceived efficacy of meropenem for managing MDR infections. Descriptive statistics summarize the data, with categorical variables shown as percentages.
Results:
This study included 412 respondents. Approximately 40% of clinicians reported that 21%–30% of patients with infections preferred meropenem. The majority of participants (72.82%) reported a preference for meropenem in meningitis, ventilator-associated pneumonia (VAP), and bloodstream infections. Nearly 81% of clinicians indicated that meropenem was the preferred drug of choice for treating gram-negative MDR pathogens. More than half of the participants (51.7%) reported that their preferred intravenous dose of meropenem was 1 g administered in two to three divided doses for treating MDR, extensively drug-resistant, or pandrug-resistant infections, while 46%…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.